HH-003 + nucleoside reverse transcriptase inhibitors + peginterferon alfa

**HH-003 + nucleoside reverse transcriptase inhibitors + peginterferon alfa** is a combination therapy under investigation primarily for chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) infection. HH-003 (Libevitug) is a fully human monoclonal antibody that targets the preS1 domain of the large envelope protein of HBV/HDV, blocking viral entry into hepatocytes by inhibiting binding to the sodium taurocholate co-transporting polypeptide (NTCP) receptor. Nucleoside reverse transcriptase inhibitors (NRTIs) inhibit the viral reverse transcriptase, interfering with viral DNA synthesis, while peginterferon alfa is an immunomodulatory agent that stimulates antiviral cellular responses through type I interferon receptor activation and JAK/STAT pathway signaling. This combination is being tested to maximize antiviral efficacy in chronic HBV and HBV/HDV co-infection, aiming for viral suppression and functional cure[1][2][3][5][7].

Brand names

Libevitug

Other names

anti-pre-S1 monoclonal antibodyanti-pre-S-1 monoclonal antibodyanti-pre-S 1 monoclonal antibodynucleoside reverse transcriptase inhibitorspeginterferon alfa